Back to Search
AARON SEIDMAN, D.O.
D.O.
Orthopaedic Surgery Physician
NPI: 1740638899IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Surgery PhysicianPrimary
Orthopaedic Surgery
Code: 207X00000X
5101022483(MI)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
UNIVERSITY OF NEW ENGLAND, COLLEGE OF OSTEO MEDICINE
Class of 2016
Research & Publications (20)
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
PMID 19596644·Clin Breast Cancer·2009
6-review
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.
PMID 19253021·J Cancer Res Clin Oncol·2009
3-trial
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
PMID 18375893·J Clin Oncol·2008
3-trial
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
PMID 18509177·J Clin Oncol·2008
8-other
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
PMID 19047117·Clin Cancer Res·2008
3-trial
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
PMID 18650151·Clin Breast Cancer·2008
6-review
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
PMID 18078353·Mol Diagn Ther·2007
6-review
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
PMID 17200358·Clin Cancer Res·2007
3-trial
Emerging targeted therapies for breast cancer.
PMID 17512452·Hematol Oncol Clin North Am·2007
6-review
Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
PMID 17927924·J Natl Compr Canc Netw·2007
8-other
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
PMID 18065731·J Clin Oncol·2007
2-rct
Systemic treatment of breast cancer. Two decades of progress.
PMID 16986346·Oncology (Williston Park)·2006
6-review
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
PMID 16942645·Clin Breast Cancer·2006
3-trial
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
PMID 16596138·Nat Clin Pract Oncol·2006
3-trial
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
PMID 16866685·J Am Geriatr Soc·2006
8-other
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
PMID 17145347·Semin Oncol·2006
6-review
Current status of dose-dense chemotherapy for breast cancer.
PMID 16273358·Cancer Chemother Pharmacol·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 28050 GRAND RIVER AVE
FARMINGTON HILLS, MI 48336 - Phone
- (248) 888-2532
Quick Facts
- NPI
- 1740638899
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile